ASCO GU 2017: BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer - Session Highlights
Orlando, Florida USA (UroToday.com) This year’s genitourinary cancer symposium allowed for Emma Hall to present long-term results from BC20001. Given that BC2001 showed that that reduced high dose volume RT rather than standard RT did not significantly reduce late side effects at limited follow up, the long term results have been anticipated [Huddart 2013].
ASCO GU 2017: Resection margins after radical cystectomy at academic versus community cancer centers. - Session Highlights
Orlando, Florida USA (UroToday.com) At this years genitourinary cancer symposium, the importance of high volume centers in care for radical cystectomy patients was re-inforced by looking at the impact of academic centers on positive margin rates. Positive margin resection correlates with worse overall survival following cystectomy.
ASCO GU 2017: Characterizing the costs of complications after cystectomy: Can we target the primary drivers? - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. Matthew Mossanen from Brigham and Women’s Hospital targeted the thromboembolic events, soft tissue and GI complications as primary cost drivers following radical cystectomy. Motivation for this study stemmed from recognising the high complication rate of cystectomy being as high as 64% at 90 days and that radical cystectomy and care for bladder cancer as a whole is one of the more expenisive diseases to care for. This study looked at financial cost of different categories of complication following radical cystectomy to identify primary forces driving expenditures.
ASCO GU 2017: Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. - Session Highlights
Orlando, Florida USA (UroToday.com) Until 2016, cisplatinum inelegible patients with advanced bladder cancer had poor outcomes due to limited effective therapies. This has been recognosied as an effective disease space for immunotherapies since recent FDA approval of checkpoint blockade for bladder cancer.
ASCO GU 2017: Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer - Session Highlights
Orlando, Florida USA (UroToday.com) The use of immunotherapy for advanced urothelial cancer continued to gain attention and excitement at this years genitourinary cancer symposium. Adding to this momentum is results from KEYNOTE-045 showing that pembrolizumab is better tolerated and more effective than standard cytotoxic chemotherapy.
ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights
Orlando, Florida USA (UroToday.com) At this years genitourinary cancers symposium in Florida, Dr. Feifer presented data which states that incorporating Abiraterone into clinical practice of Urologists is a realistic and feasible process. The Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC) is a non-Interventional observational study phase IV clinical trial (NCT02364531).
ASCO GU 2017: Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. - Session Highlights
Orlando, Florida USA (UroToday.com) Puneet Dhillon from Southfield Michigan addressed the important issue of informed decision making to a high risk population in his abstract presented at the 2017 Genitourinary Cancer Symposium. His team recognised the potential that health-education may reduce disparities.